Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Review Article

Effect of the renin–angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function

Journal of Human Hypertension volume 18, pages 599–606 (2004)Cite this article

Abstract

Plasma renin activity and cardiovascular disease (CVD) incidence correlate closely in people with hypertension. The effects of angiotensin II (Ang II) on blood pressure (BP) are important in hypertensive patients; accumulating data suggest that the growth effects of Ang II in the cardiovascular system play a critical role in the development of atherosclerosis. Atherosclerosis development in hypertensive patients requires fundamental changes in endothelial structure and function. Key among the factors that may affect the endothelium is the renin–angiotensin–bradykinin system. Ang II, independent of other environmental and neurohormonal factors, mediates the vessel wall changes critical for the development of atherosclerotic disease. A strong correlation appears to exist between Ang II and CVD. Blockade of the renin–angiotensin system has a major impact on arterial structure and function independent of BP. Certain angiotensin-converting enzyme (ACE) inhibitors produce significant improvements in arterial compliance, which may yield a reduction in cardiovascular events. Blockade of the neurohormonal system may be a critical first-line approach to management of hypertension in an effort to prevent or reverse endothelial dysfunction. Moreover, the effects of ACE inhibition, in addition to its effect on BP, suggest that this therapeutic approach may be appropriate for managing patients at risk of CVD who do not yet have hypertension. The ideal antihypertensive agent should yield smooth, consistent BP control over the entire 24-hour period, both to avoid BP variability that places patients at increased risk of cardiovascular events and to offer protection during the vulnerable early morning hours when patients are well known to be at high risk.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  1. American Heart Association. Heart and Stroke Facts Statistical Update. American Heart Association: Dallas, TX, 2002.

  2. McMahon S et al. Blood pressure, stroke and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution. Lancet 1990; 335: 765–774.

    Article  Google Scholar 

  3. Grimm RH, et al, for the MIDAS Research Group. A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis: the multicenter isradipine diuretic atherosclerosis study (MIDAS). Drugs 1990; 4 (Suppl 2): 38–43.

    Article  Google Scholar 

  4. Havlik RJ et al. Antihypertensive drug therapy and survival by treatment status in a national survey. Hypertension 1989; 1 (Suppl I): I-28–I-32.

    Article  Google Scholar 

  5. Kannel WB . Blood pressure as a cardiovascular risk factor. Prevention and treatment. JAMA 1996; 275: 1571–1576.

    CAS  PubMed  Google Scholar 

  6. Celentano A et al. Blood pressure and cardiac morphology in young children of hypertensive subjects. J Hypertens 1988; 6 (Suppl 4): S107–S109.

    Article  CAS  Google Scholar 

  7. Dzau VJ . Atherosclerosis and hypertension: mechanisms and interrelationships. J Cardiovasc Pharmacol 1990; 15 (Suppl 5): S59–S64.

    Article  CAS  PubMed  Google Scholar 

  8. Dzau VJ . Tissue renin–angiotensin system: physiologic and pharmacologic implications. Circulation 1988; 77: I1–I3.

    Article  CAS  PubMed  Google Scholar 

  9. Glasser SP, Selwyn AP, Ganz P . Atherosclerosis: risk factors and the vascular endothelium. Am Heart J 1996; 131: 379–384.

    Article  CAS  PubMed  Google Scholar 

  10. Neutel JM et al. Heredity and hypertension: impact on metabolic characteristics. Am Heart J 1992; 124: 435–440.

    Article  CAS  PubMed  Google Scholar 

  11. Gibbons GH . Endothelial function as a determinant of vascular function and structure: a new therapeutic target. Am J Cardiol 1997; 79 (Suppl 5A): 3–8.

    Article  CAS  PubMed  Google Scholar 

  12. Neutel JM, Smith DHG, Graettinger WF, Weber MA . Dependency of arterial compliance on circulating neuroendocrine and metabolic factors in normal subjects. Am J Cardiol 1992; 69: 1340–1344.

    Article  CAS  PubMed  Google Scholar 

  13. Neutel JM . Why lowering blood pressure is not enough. The hypertension syndrome and the clinical context of cardiovascular risk reduction. Heart Dis 2000; 2: 370–374.

    CAS  PubMed  Google Scholar 

  14. Lonn EM et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90: 2056–2069.

    Article  CAS  PubMed  Google Scholar 

  15. Brunner HR et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972; 286: 441–449.

    Article  CAS  PubMed  Google Scholar 

  16. Alderman MH et al. Association of the renin–sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324: 1098–1104.

    Article  CAS  PubMed  Google Scholar 

  17. Laragh J . Review course. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens 2001; 41: 84–89.

    Article  Google Scholar 

  18. Dzau VJ . Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047–1052.

    Article  CAS  PubMed  Google Scholar 

  19. Gibbons GH . Endothelial function as a determinant of vascular function and structure: a new therapeutic target. Am J Cardiol 1997; 79: 3–8.

    Article  CAS  PubMed  Google Scholar 

  20. Dzau VJ . Tissue renin–angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993; 153: 937–942.

    Article  CAS  PubMed  Google Scholar 

  21. Ross R . Atherosclerosis—an inflammatory disease. N Engl J Med 1999; 340: 115–126.

    Article  CAS  PubMed  Google Scholar 

  22. Nickenig G et al. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997; 95: 473–478.

    Article  CAS  PubMed  Google Scholar 

  23. de las Heras N et al. AT1 receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits. Hypertension 1999; 34 (Part 2): 969–997.

    Article  CAS  PubMed  Google Scholar 

  24. Gibbons GH, Dzau VJ . The emerging concept of vascular remodeling. N Engl J Med 1994; 330: 1431–1438.

    Article  CAS  PubMed  Google Scholar 

  25. Cohn JN et al. Noninvasive pulse wave analysis for the early detection of vascular disease. Hypertension 1995; 26: 503–508.

    Article  CAS  PubMed  Google Scholar 

  26. Daugherty A, Manning MW, Cassis LA . Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000; 105: 1605–1612.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Baron AD . The coupling of glucose metabolism and perfusion in human skeletal muscle. The potential role of endothelium-derived nitric oxide. Diabetes 1996; 45 (Suppl 1): S105–S109.

    CAS  PubMed  Google Scholar 

  28. Baron AD . Vascular reactivity. Am J Cardiol 1999; 84: 25J–27J.

    Article  CAS  PubMed  Google Scholar 

  29. Baron AD . Insulin and the vasculature—old actors, new roles. J Invest Med 1996; 44: 406–412.

    CAS  Google Scholar 

  30. Weber MA, Smith DHG, Neutel JM, Graettinger WF . Arterial properties of early hypertension. J Hum Hyper tens 1991; 5: 417–423.

    CAS  Google Scholar 

  31. Clozel J-P, Kuhn H, Hefti F . Decreases of vascular hypertrophy in four different types of arteries in spontaneously hypertensive rats. Am J Med 1989; 87 (Suppl 6B): 92S–95S.

    Article  CAS  PubMed  Google Scholar 

  32. Asmar RG et al. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation 1988; 78: 941–950.

    Article  CAS  PubMed  Google Scholar 

  33. Sihm I et al. Normalization of structural cardiovascular changes during antihypertensive treatment with a regimen based on the ACE-inhibitor perindopril. Blood Press 1995; 4: 241–248.

    Article  CAS  PubMed  Google Scholar 

  34. Thybo NK et al. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995; 25 (Part I): 474–481.

    Article  CAS  PubMed  Google Scholar 

  35. Weber MA . The angiotensin II receptor blockers: opportunities across the spectrum of cardiovascular disease. Rev Cardiovasc Med 2002; 3: 183–191.

    Article  PubMed  Google Scholar 

  36. White WB, Dey HM, Schulman P . Assessment of the daily blood pressure load as a determinant of cardiac function in patients with mild-to-moderate hypertension. Am Heart J 1989; 118: 782–795.

    Article  CAS  PubMed  Google Scholar 

  37. Frattola A et al. Prognostic value of 24-hour blood pressure variability. J Hypertens 1993; 11: 1133–1137.

    Article  CAS  PubMed  Google Scholar 

  38. Deedwania PC, Nelson JR . Pathophysiology of silent myocardial ischemia during daily life. Hemodynamic evaluation by simultaneous electrocardiographic and blood pressure monitoring. Circulation 1990; 82: 1296–1304.

    Article  CAS  PubMed  Google Scholar 

  39. Muller JE et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985; 313: 1315–1322.

    Article  CAS  PubMed  Google Scholar 

  40. White CM . Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy 1998; 18: 588–599.

    CAS  PubMed  Google Scholar 

  41. Monopril® (product information). Bristol-Myers Squibb. Physician's Desk Reference®, Available at: www.pdrel.com/pdr/static.htm?path=pdrel/pdr/10451000.htm. Accessed on 29 August 2002.

  42. Lotensin® (product information). Novartis Pharmaceuticals Corporation. Physician's Desk Reference®, 58th edn. Thomson PDR: Montvale,NJ, 2004, pp. 2279–2284.

  43. Aceon® (product information). Solvay Pharmaceuticals, Inc. Physician's Desk Reference®, 58th edn. Thomson PDR: Montvale, NJ. 2004, pp. 3163–3165.

  44. Accupril® (product information). Parke-Davis, A Division of Warner-Lambert Company LLC, A Pfizer Company. Physician's Desk Reference, 58th edn. Thomson PDR: Montvale, NJ, 2004, pp. 2516–2519.

  45. Altace® (product information). Monarch Pharmaceuticals a wholly owned subsidiary of King Pharmaceuticals, Inc. Physician's Desk Reference®, 58th edn. Thomson PDR: Montvale, NJ, 2004, pp. 2142–2145.

  46. Mavik® (product information). Abbott Laboratories. Physician's Desk Reference®, 58th edn. Thomson PDR: Montvale, NJ, 2004, pp. 489–491.

  47. Meredith PA, Elliott HL . Concentration–effect relationships and implications for trough-to-peak ratio. Am J Hypertens 1996; 9: 66S–70S.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

I thank Solvay Pharmaceuticals for its support for this work.

Author information

Authors and Affiliations

  1. Orange County Heart Institute, Orange, CA, USA

    J M Neutel

Authors
  1. J M Neutel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J M Neutel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neutel, J. Effect of the renin–angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function. J Hum Hypertens 18, 599–606 (2004). https://doi.org/10.1038/sj.jhh.1001714

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1001714

Keywords

Search

Advanced search

Quick links